Statins represent a major class of drugs for treatment of hypercholesterolemia due to their ability to inhibit de novo cholesterol synthesis, namely the rate-limiting step of mevalonate pathway catalyzed by HMG-CoA reductase. This evidence concerns the gene HMGCR and familial hypercholesterolemia.